Go Green, Go Online!
JDDonline.com

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.

2011 SUBJECT INDEX

Letters after article titles refer to the following: BC = Brief Communication; CR = Case Reports; CTR = Clinical Trial Review; DP = DermPearls; NVR = News, Views, and Reviews; PP = Pipeline Previews; RR = Resident Rounds; RS = Resident Spotlight

A
Abatacept, randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
AbobotulinumtoxinA (ABO) in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125
comparing clinical attributes of ABO and onabotulinumtoxinA utilizing Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
AC-820 (nalfurafine HCl), randomized-withdrawal phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91
Açai berry, aesthetic benefits of natural ingredients in skin care, s11 (September)
Actinie cheilitis (AC), treatment by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1249
Actinic keratoses (AK)
comparison of cryotherapy and imiquimod for, lesion clearance, safety, and skin quality outcomes in, 1432
effect of retinoid pretreatment on outcomes of photodynamic therapy for AK of hand and forearm, 1124
Gracey was removes FDA approval for Zyclara Cream 2.5% (PP), 1076
imiquimod cream in combination with cryotherapy in treatment of hypertrophic AK (CTR), 426
long-term sustained complete clearance of AK of face or balding scalp after imiquimod treatment, 165
nonablative 1927 nm fractional resurfacing for AK of face or balding scalp after imiquimod treatment, 165
prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for, 372
randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for AK of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
treatment with imiquimod cream followed by photodynamic therapy (CTR), 426
trends in treatment of, 16
Acupuncture for pruritus in atopic dermatitis (CTR), 90
Adalimumab
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis
and subsequent complication-free treatment with alternate TNF-α blockers (CR), 914
and narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to, 396
treatment of recalciitrant generalized granuloma annulare with (CR), 1466
Adapalene
adapalene gel 0.3% in atrophic acne scars (CTR), 96
Epiduo pediatric acne study (CTR), 90, 312
rethinking treatment of acne in severe patient, s8 (June)
study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
in topical monotherapy for acne, compared to fixed-combination therapy, 636
Adherence to treatment
in once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135
patient experience and management of dryness and irritation from acne treatment affecting, 605
in topical rosacea therapy, vehicle formulations affecting, 627
AEB071, dose finding study assessing psoriasis area and severity index in plaque psoriasis (CTR), 92
Aging
clinical evidence for activity of tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
dermal fillers in skin of color population, 494
evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler in, 673
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
safety and efficacy of calcium hydroxyapatite for rejuvenation of aging hand, 47
tower technique for injection of hyaluronic acid fillers in, 1277
AIDS. See HIV infection and AIDS
AIN457, dose-ranging study in moderate-to-severe chronic plaque-type psoriasis (CTR), 93
Albert Einstein College of Medicine Unified Division of Dermatology
eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
intralymphatic histiocytosis associated with orthopedic implants (RR), 1208
program spotlight on Residency Program
Aldactone
sound- alike and look- alike terms in dermatology (RR), 1196
Alefacept
for nephrogenic systemic fibrosis (CR), 922
Alexandrite laser
comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
Aloe vera
aesthetic benefits of natural ingredients in skin care, s11 (September)
in atopic dermatitis and other inflammatory skin diseases, s6 (September)
Aloesin
aesthetic benefits of natural ingredients in skin care, s11 (September)
Alopecia
approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98
dutasteride versus placebo and finasteride in men with androgenetic alopecia (CTR), 936
novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
safety and efficacy of clobetasol propionate 0.05% emollient foam in (CTR), 1077
safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
scalp hyperkeratosis and alopecia in children of color, 511
START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
Amazingel
compared to other polycrylamide hydrogels, 1370
AMG 157, safety study in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
Aminolevulinic acid (ALA)
effect of retinoid pretreatment on outcomes of ALA-PDT for actinic keratosis of hand and forearm, 1124
preliminary results of hidradenitis suppurativa treatment with ALA-PDT, 381
prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratoses, 372
randomized blinded bilateral intra-individual vehicle-controlled trial of ALA-PDT and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
severe cutaneous reaction to ALA-PDT with blue light (CR), 1057
treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240
Amiodarone
Q-switched laser treatment of amiodarone pigmentation (CR), 1316
Ammonium lactate emollient foam vehicle, salicylic acid 6% in, for scalp psoriasis, 270
Anakinra
effective for severe Muckle-Wells syndrome (PP), 214
pilot study in severe atopic dermatitis (CTR), 313
Anal cancer
FDA approves Gardasil to prevent (PP), 325
Anal fissures
FDA approval of Rectiv for pain associated with (PP), 939
Androgens
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
Anti-inflammatory agents
cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160
in natural ingredients, s12 (September)
randomized study of dapsone gel 5% in combination with tazotere cream 0.1% in acne vulgaris, 783
Antimicrobial drugs
antibiotic resistance: an editorial review with recommendations, 724
FDA approves Cefaroline for MRSA (PP), 104
recent advances and future directions in medical management of skin disease, 28
rethinking treatment of acne in severe patient, s8 (June)
Antioxidants
assessment of antioxidative capacity kinetics of topical antioxidants, 262
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
in natural ingredients, s11 (September)
Apremilast
open label pilot study in rosacea (CTR), 313
phase 2 open-label investigator-initiated study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
Aquamid
compared to other polycrylamide hydrogels, 1370
Aquaphor Healing Ointment
compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
Arbutin
eaesthetic benefits of natural ingredients in skin care, s11 (September)
Anhydrias
isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
L-Ascorbic acid
evaluation of prescription barrier creams in mild-to-moderate atopic dermatitis (RS), 928
study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
Asian patients
community-based survey of skin conditions
INDEX OF ARTICLES
Journal of Drugs in Dermatology

A
Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

B
B cell lymphoma, diffuse large, associated with biologic and other investigational agents in psoriasis (CR), 80
Barrier creams, prescription, compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
Barrier function of skin. See Skin barrier function
Basal cell carcinoma (BCC)
electronic brachytherapy for treatment of (CTR), 206
Genentech submits New Drug Application to FDA for (PP), 1340
study on efficacy and safety of GDC-0449 in (CTR), 206
ulerated nodal nasal BCC successfully treated with imiquimod 5% cream (letter to the editor), 240
Belimumab, FDA approves Benlysta for lupus erythematosus (PP), 806
Benzocaine, methemoglobinemia risk from benzocaine topical products (PP), 684
Benzoyl peroxide
Acanya gel acne therapy available in pump (PP), 1479
in combination treatment for moderate-to-severe acne (CTR), 90
Epipduo pediatric acne study (CTR), 90, 312
in fixed-combination therapy for acne, compared to retinoid monotherapy, 636
patient experience and management of dryness and irritation from acne treatment with, 605
rethinking treatment of acne in severe patient, s8 (June)
safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
study comparing Azcione plus Differin to Duac plus Differin in severe facial acne (CTR), 312
Betamethasone dipropionate
LEO Pharma launches $0 copay program for Taconex plaque psoriasis treatments (PP), 683
topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of tazarotec after step-down dose in moderate-to-severe plaque psoriasis, 878
Bexarotene, study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209
Bicillin-LA versus placebo for chronic plaque-type psoriasis unresponsive to topical medications (CTR), 317
Bimatoprost
novel treatment of female-pattern baldness (letter to the editor), 240

Botulinum toxin
Allergan cell-based assay for BOTOX (PP), 938
in combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1146
cosmeceutical and nutraceutical horizons, 24
determined double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718
Biologics
diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
impact on disease and treatment burden of psoriasis, 189
Biopsy diagnosis
clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930
comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
Bladder cancer
clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
review of chemopreventative effects of oral retinoids for, 1292
Blisters, autoimmune-mediated (RR), 491
Blue light
gerandomized blinded bilateral intranidal vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
severe cutaneous reaction to photodynamic therapy with (CR), 1057
treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
Botanical products
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
cosmeceutical and nutraceutical horizons, 24
evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensometry methods, 1116
randomized double-blind petrolatum-controlled study on efficacy of orogano extract ointment in wound healing, 1168
and concerns in South Asian Americans, 524
treating lentigines with Q-switched Alexandrite laser in (DP), s14
ASP015K, study to explore efficacy and safety in moderate-to-severe psoriasis (CTR), 93, 315
Atopic dermatitis (AD)
acupressure for pruritus in (CTR), 90
bilateral comparison study of pimecrolimus cream 1% and medical device cream in, 735
new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714
pediatric longitudinal evaluation on long-term safety of Protopic Ointment for (CTR), 1217
phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
pilot study of Anakira in severe AD (CTR), 313
recent advances in treatment of, 28
safety study of AMG 157 in healthy subjects and subjects with AD (CTR), 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in (CTR), 314
stratum corneum abnormalities in, s9 (October)

Autoimmune conditions
blisters in (RR), 491
bullous pemphigoid after herpes zoster vaccine administration (CR), 1328
effectiveness of topical tacrolimus for vitiligo (RR), 491
bullous pemphigoid after herpes zoster (PT), 348
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939

Azfice-T
FDA approval of Filibrocill Science LAVIP (PP), 939
in nasolabial folds and wrinkles (PP), 325, 939
assessing botulinum neurotoxin type-A activity, 968
in keloid management (NVR), 549
long-term efficacy and potencies of botulinum toxin A and B (PP), 324
rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis (CR), 1013
Brachytherapy, electronic, for non-melanoma skin cancer treatment (T), 206
Breast cancer
clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
review of chemopreventative effects of oral retinoids for, 1292
Breast reconstructive surgery, case report of pyoderma gangrenosum following treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
Briakinumab withdrawal from FDA review (PP), 435
Brief Communications (BC)
assessor-blinded study of metabolic syndrome and surrogates markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts, 900
CD70 and Th17 are involved in human contact dermatitis, 666
CD07805/47 topical gel
Calcitonin, effectiveness of clobetasol propionate ointment in plaque psoriasis, 158
Calcipotriene FDA approves Soralix foam (PP), 103
Calcipotriene topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
Calcitriol multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
Calcium hydroxyapatite, management of impending necrosis associated with soft tissue filler injections (CR), 1007
Cardiovascular disease risk
metabolic syndrome and surrogates markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
psoriasis drugs not linked to increased heart risks (PP), 1215
Case Reports (CR)
alefacept therapy for nephrogenic systemic fibrosis, 922
bullous pemphigoid after herpes zoster vaccine administration, 1328
case of lichen planus following Tdap vaccination, 1067
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
chemical burn from povidone-iodine, 414
carbamazepine-induced drug reaction with sorafenib, 1331
diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis, 80
erythema multiforme-like drug reaction to sorafenib, 1462
fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil in pemphigus foliaceus in an immunocompromised patient, 418
fixed drug eruption associated with iohexol intravenous contrast media, 802
levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome, 1204
management of impending necrosis associated with soft tissue filler injections, 1007
metallic taste as side effect of topical fluorouracil, 1201
modified Tripier flap for lateral eyelid reconstruction, 199
Meds micrographic surgery for cutaneous lymphadenoma, 1324
multiple facial burns with new Thermage CPT system (CR), 1320
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-α blockers, 914
novel KRT14 mutation in epidermolytic bullous simplex with mottled pigmentation, 926
novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution, 795
pigmentary changes in patient treatment with imatinib, 1062
post-herpetic itch resolved with gabapentin, 85
Q-switched laser treatment of amiodarone pigmentation, 1316
regression of internal malignant melanomas after topical application of imiquimod, 302
rituximab dosing in refractory pemphigus vulgaris in adolescent male, 202
same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis, 1013
severe cutaneous reaction to photodynamic therapy with blue light, 1057
sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma, 308
tamoxifen-induced hirsutism, 799
tattoo sites and psoriasis, 1199
treatment of peristomal pyoderma gangrenosum with topical crushed dapsone, 1059
treatment of recalcitrant generalized granuloma annulare with adalimumab, 1468
vesiculobulbous variant of adult T-cell leukemia/lymphoma in a Caribbean émigré, 1469
CC-10004 for prurigo nodularis (CTR), 91
CD70 and Th17 involvement in human contact sensitivity (BC), 1192
CD07805/47 topical gel, phase 3 efficacy and study in facial erythema associated with rosacea (CTR), 1216
Ceramide
bilateral comparison study of pimecrolimus cream 1% and ceramide-hyaluronic acid emollient foam in atopic dermatitis, 666
ceramide-containing barrier repair cream compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
Cetaphil Restoraderm System compared to standard skin care in infants with atopic dermatitis (CTR), 1486
Chamomile in atopic dermatitis and other inflammatory skin diseases, s6 (September)
Chelitis, actinic, treatment by photodynamic
therapy with 5-aminolevulinic acid and blue light activation, 1240
Chemical burn from povidone-iodine (CR), 414
Chemical peels in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melanoma, 1439
Chemoprevention, review of chemopreventive effects of oral retinoids for internal neoplasms, 1292
Chemotherapy, START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
Children. See Pediatric dermatology
Chitosan, treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
Chloracne-like drug eruption associated with sorafenib (CR), 1331
Chorioretinopathy, central serous, associated with topical corticosteroids in psoriasis (CR), 918
Citrus bioflavanoid blend, randomized placebo-controlled double-blind study on efficacy versus placebo in men with androgenetic alopecia, 936
effects of pulsed-dyed laser on scar formation, 96
Cleansing product in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
Clindamycin Acanya gel acne therapy available in pump versus placebo for chronic plaque psoriasis, 92
dose finding study of AEBO701 assessing psoriasis area and severity index in plaque psoriasis, 92
dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis, 93
dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris, 426
dutasteride versus placebo and finasteride in patients with androgenetic alopecia, 936
effects of pulsed-dyed laser on scar formation, 96
efficacy and safety of different concentrations of ZK245186 in atopic dermatitis, 1486
electrically bradychardia for non-melanoma skin cancer treatment, 206
Epiduo pediatric acne study, 90, 312
evaluation of efficacy of lanthanum carbonate in calciphylaxis, 1342
gemcitabine and pemetrexed disodium in advanced pancreatic cancer, 426
imiquimod cream 2.5% in treatment of warts, 1343
Impetigo, treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
In vivo confocal microscopy of cutaneous neoplasms and normal skin, 318
Japan Open Label Pilot Study of Apremilast in Severe Acne, 1077
成功的Treatment of Melasma, 1439
Neuregulin-1, treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
Neutrogena, phase 3 study to explore efficacy and safety of ZR2104 in moderate-to-severe plaque psoriasis, 1216
Niacinamide, treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
Ninhydrin, treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
One-year study on efficacy and safety of CP-690,550 in moderate-to-severe chronic plaque psoriasis, 94
Pilot study of Apremilast in Severe Acne, 1077
Ranitidine HCl (AC-820) in hemodialysis and uramic pruritus, 917
treatment efficacy of bimatoprost in women with female pattern hair loss, 936
treatment efficacy of clofetastone propionate 0.05% emollient foam in alopecia, 1077
safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis, 95
treatment efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis, 1216
Sézary syndrome, 208
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis, 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis, 314
sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma, 207
spectral diagnosis of cutaneous malignancy, 318
START (Swiss Taxotere Alopecia Prevention Trial), 936
study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma, 209
study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis, 92, 314
study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome, 97
study of local efficacy and safety of R2077 in moderate-to-severe plaque psoriasis, 1077
study of LV2439821 in moderate-to-severe psoriasis, 94
study of new drug treatment for acne, 687
study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides, 209
study of ultrasonography with elastography in calciphylaxis, 1343
study of new drug treatment for acne, 687
study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis, 92, 314
study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome, 97
study of local efficacy and safety of R2077 in moderate-to-severe plaque psoriasis, 1077
study of LV2439821 in moderate-to-severe psoriasis, 94
study of new drug treatment for acne, 687
study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides, 209
study of ultrasonography with elastography in skin neoplasms, 319
study on efficacy and safety of GDC-0449 in moderate-to-severe plaque psoriasis, 1216
study to explore efficacy and safety of AS015K in moderate-to-severe
commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers (letter to the editor), 964

cosmeceutical and nutraceutical horizons, 24
efficacy and tolerability of new monophasic double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134
guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673

open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145

rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974

safety and efficacy of calcium hydroxyapatite for rejuvenation of aging hand, 47

in skin of color population, 494
tower technique for injection of hyaluronic acid fillers in, 1277

DemaPACE device for diabetic foot ulcers (PP), 325

Dermatitis

atopic. See Atopic dermatitis (AD)

CD70 and Th17 in contact dermatitis (BC), 1192
dapsone gel 5% for dermatitis herpetiformis (CTR), 314

managing epidermal barrier function in treatment of dermatoses, s13 (October)

open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895

open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398

phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928

Dermatofibrosarcoma protuberans, malignancy arising with cutaneous tattoo, 837

Dermatology education. See Resident Rounds (RR); Training

Dermatomyositis, fulminant

dermatology education.

Dermatofibrosarcoma protuberans

laser hair removal pearls in skin of color, s12

laser hair removal in ethnic skin, principles and practical aspects of, s17

fractional laser resurfacing for acne scarring

diode 810 nm laser as safe, effective modality in treating acne patients with skin of color, s25 (December)
treating lentigines in Asian patients with Q-switched Alexandrite laser, s14 (December)

Devices and equipment

Alma Lasers introduces iPixel fractional ablative technology (PP), 805

clinical trial of Dermacorder for detecting malignant skin lesions (CTR), 317

CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system (PP), 1478

dermaPACE device for diabetic foot ulcers (PP), 325

Elm International introduces Pellevé Wrinkle Reduction System to European market (PP), 938

FDA clearance of EndyMed Fractional Skin Rejuvenation System (PP), 213

FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341

FDA panel votes in favor of MelaFind device (PP), 1340

spectral diagnosis probe in cutaneous malignancy detection (CTR), 318

Syneron devices at 22nd world Congress of Dermatology (PP), 805

Dexpanthenol in atopic dermatitis and other inflammatory skin diseases, s6 (September)

Diabetes mellitus, dermaPACE device for diabetic foot ulcers (PP), 325

Diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

Dimethyl ether and propane

compared to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174

Dioderivative. See Diode laser

novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics, s10 (December)

strategies minimizing irritation and iatrogenic post-inflammationary pigmentation in treating acne patients with skin of color, s25 (December)
treating lentigines in Asian patients with Q-switched Alexandrite laser, s14 (December)

Doxycline

compared to minocycline for management of acne (letter to the editor), 965, 966

rethinking treatment of acne in severe patient, s8 (June)

self-reported treatment impressions and satisfaction of papulopustular rosacea patients treated with doxycycline USP 40 mg capsules, 1376

Drug calendar, electronic, in cutaneous drug eruptions, 1430

Drug reactions/toxicity

case of lichen planus following Tdap vaccination (CR), 1067

drugs and clinical courses of drug-induced urticaria, 1019

central serous chorioretinopathy associated with topical corticosteroids in psoriasis (CR), 918

chemical burn from pivovdine-iodine (CR), 414

chloracne-like drug eruption associated with sorafenib (CR), 1331

clinical trial safety and mortality analysis of etanercept across approved indications, 285

creation of electronic drug calendar in drug hypersensitivity, 1430

cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215

cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160

erthema multiforme-like drug reaction to sorafenib (CR), 1462

fixed drug eruption associated with iohexol Intravenous contrast media (CR), 916

iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070

isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204

levamisole-induced retiform purpura (RR), 217

metallic taste as side effect of topical fluorouracil (CR), 1201

methemoglobinemia risk from benzocaine topical products (PP), 684

pigmentary changes in patient treatment with imatinib (CR), 1062

Q-switched laser treatment of amiodarone pigmentation (CR), 1316

reported adverse effects of isotretinoin and systemic corticosteroids (RR), 287

short-term and low-dose oral fluorconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features (CR), 308

tamoxifen-induced hirsutism (CR), 799

Drug resistance

antibiotic resistance: an editorial review with recommendations, 724

FDA approves Ceftriaxone for MRSA (PP), 104

recent advances and future directions in
medical management of skin disease, 28

**Dutasteride**
in female androgenetic alopecia (NVR), 98 versus placebo and finasteride in men with androgenetic alopecia (CTR), 936

**Dyschromia**, laser treatment with novel 607 nm pulsed-dye laser, 388

**E**

Eastern Virginia Medical School Residency Program

program spotlight on (RR), 344 ticks of dermatologic significance (RR), 365 viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422

Editorials

cancer: this war is personal, 237 commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers, 964 cosmetic treatments on skin of color, a unique challenge, s4 (December) defining the future of dermatology, 15 doxycycline versus minocycline for management of acne, 965, 966 introduction to demystifying acne algorithms supplement, s7 (June) introduction to DermPearls supplement, s4 (December) JDD goes international, 581 JDD receives impact factor ranking of 1,954, 1234 lessons from an exemplary physician in private setting, 238 new face of fillers: why evidence and experience both count, 964 role of stratum corneum in healthy and diseased skin, s4 (October) short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360 skin of color: progress made, challenges remain, 459 ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240 why are dermatologists still talking about acne? because so many people have it, and we are always seeking better ways to manage it, 575

Eflaximab, diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

**Elastography**, ultrasonic, in skin neoplasms (CTR), 319

**Electrocardiography**, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

**Electronic medical records**, creation of electronic drug calendar in drug hypersensitivity, 1430

Eletone cream, bilateral comparison study of pimecrolimus cream 1% and medical device cream in atopic dermatitis, 735

**Epidermolysis bullosa simplex** with mottled pigmentation, novel KRT14 mutation in (CR), 926

Erbium:YAG micropore treatment, prospective randomized trial on effects of fluence settings for facial photoaging, 179

Erlotinib, phase 2 trial in squamous cell cancer prior to surgery or radiation (CTR), 207

**Erythema**
erythema multiforme-like drug reaction to sorafenib (CR), 1462 fulminant dermatomyositis with flagellate erythema (RR), 902 phase 3 efficacy and study of CD07805/47 topical gel in facial erythema thalidomide and complement activation in erythema nodosum leprosum, 274

Erythrasma, case of trichomycosis axillaris and (RR), 1472

Erythromycin in fixed-combination therapy for acne, compared to retinoid monotherapy, 636

**Estrogen**, advantages of oral contraceptives and spironolactone for women with acne (DP), 941

Etanercept

clinical trial and safety trial analysis across approved indications, 289 open-label prospective cohort pilot study on efficacy and safety in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396 retrospective study of racial and ethnic variations in psoriasis treatment with, 896 safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216 as sole treatment for grade I acute graft versus host disease (CTR), 1487 topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878

Ethnicity. See Race/ethnicity

**Eretinate**, depression associated with, 409

**Extensiometry**, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using, 1116

**Eyelid**, modified Tripler flap for lateral eyelid reconstruction (CR), 199

**F**

**Facial lipoatrophy**, evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

**Facial rejuvenation**
clinical evidence for activity of tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active ingredient in skin cosmetic, 1102 aesthetic benefits of natural ingredients in skin care, s12 (September) in atopic dermatitis and other inflammatory skin diseases, s6 (September)

**Fibroblasts**
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753 green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096

**Fibrosis, nephrogenic systemic** alefacept therapy for (CR), 922 case report and literature review (RR), 622

**Finasteride**
dutasteride versus placebo and finasteride in men with androgenetic alopecia (CTR), 936 in female androgenetic alopecia (NVR), 98

**Fitzpatrick skin types**
acne in patients with skin of color, s13 (June) fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December) safety and efficacy of cosmetic laser treatments for skin of color, 35 ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654

**Fixed drug eruption**
associated with iohexol intravenous contrast media (CR), 802

Fluticasone propionate, injection lipolysis of
Fluocinonide
effects of novel formulation on skin barrier function in atopic dermatitis, 171 efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis (CTR), 1486

5-Fluorouracil
metallic taste as side effect of (CR), 1201 optimal use in keloids (NVR), 548 prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372

Fluticasone propionate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103

Follistatin, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308

Food and Drug Administration
Abbott withdraws briakinumab from FDA
in men with androgenetic alopecia (CTR), 936

FDA grants marketing clearance for
HairMax Dual 12 home-use laser
phototherapy device (PP), 1341

hair findings board review (RR), 1464

hair regrowth following a Wnt- and follistatin-
containing treatment, safety and efficacy in first-in-man phase 1
clinical trials, 1308

laser hair removal in gynecomastic skin, principles
and practical aspects of (DP), s17
(December)

laser hair removal pearls in skin of color (DP),
s12 (December)

novel 0.65 millisecond pulsed 1064 nm laser
to treat skin of color without skin
cooling or to treat aesthetics (DP), s10
(December)

novel treatment of female-pattern
androgenetic alopecia with injected
bimatoprost 0.03% solution (CR), 795

randomized double-blind placebo-controlled
clinical trial on efficacy of abatacept
costimulatory blockade in alopecia
areata (editor), 934

ROGAINE introduces Unscented Topical Foam
(PP), 1076

role of inflammation and immunity in
pathogenesis of androgenetic
alopecia, 1404

safety and efficacy of clobetasol propionate
0.05% emollient foam in alopecia
(CTR), 1077

safety and efficacy of laser hair removal for
skin of color, 35

safety and efficacy study of bimatoprost in
women with female pattern hair
loss (CTR), 936

sculp hyperkeratosis and alopecia in children
of color, 511

START (Swiss Taxotere Alopecia Prevention
Trial (CTRI), 936

tamoxifen-induced hirsutism (CR), 799

Hand

open-label study on treatment of mild-to-
moderate chronic hand dermatitis with
clobetasol propionate 0.05% emollient
foam, 1398

safety and efficacy of calcium hydroxylapate
for rejuvenation of aging hand, 47

Harvard Combined Dermatology Residency
Training Program

high-yield dermatologic signs in (RR), 197
program spotlight on (RR), 186

Head and neck cancer

Mohs micrographic surgery for cutaneous
lymphadenoma (CR), 1324

review of chemopreventive effects of oral
retinoids for, 1292

Head lice, FDA approves Natroba for (PP), 434

Health care costs

increased prevalence of psychiatric disorders
and health care-associated costs in
moderate-to-severe psoriasis, 843

medication choice and associated health care
outcomes and costs in acne and
acne-related conditions, 766

Health care outcomes, medication choice and
associated health care outcomes and
costs in acne and acne-related conditions, 766

Heart

isotretinoin does not prolong QT intervals
and QT dispersion in severe acne:
A surprising finding for a drug with
numerous side effects, 710

metabolic syndrome and surrogate markers
of increased cardiovascular risk in
children with moderate-to-severe
psoriasis compared to age-matched
population with warts (BC), 900

psoriasis drugs not linked to increased heart
risks (PP), 1215

Hemodialysis, randomized-withdrawal phase
3 study on safety and efficacy of
nafurtaline HCI (AG-820) for uremic
pruritus in (CTR), 91

Hepatocellular carcinoma

clinical clues and patterns in biopsy diagnosis
of cutaneous metastases of (INVR),
678, 930

review of chemopreventive effects of oral
retinoids for, 1292

sorafenib-induced eruptive squamous cell
carcinomas with keratoacanthoma-like
features in (CR), 308

Herbal extracts

evaluation of moisturizing effect of
methanolic extract of five medicinal
plants incorporated into cream
bases using impedance and
extensimetry methods, 1116

randomized double-blind petrolatum-
controlled study on efficacy of
oregano extract ointment in wound
healing, 1168

Herpes simplex labialis, randomized double-blind
placebo-controlled multi-center trial of
zinc for (CTR), 1343

Herpes zoster

bullous pemphigoid after herpes zoster
vaccine administration (CR), 1328

herpes zoster vaccine reduces zoster risk (PP),
324

post-herpetic itch resolved with gabapentin
(CR), 85

Hidradenitis suppurativa, preliminary results of
treatment with ALA-PDT, 381

Hirsutism

comparison of sequential treatment with
diole and alexandrite lasers versus
alexandrite laser alone in, 1255

safety and efficacy of laser hair removal in, 35

tamoxifen-induced (CR), 799

Histiocytosis, intralymphatic, associated with
orthopedic implants (RR), 1208

Histology, histological and immunohistochemical
evaluation of intense pulsed light
photorejuvenation, 1246

HIV infection and AIDS

erosive and desquamative syphilis associated
with mucostis in setting of AIDS
(CR), 1335

evolution of injectable poly-L-lactic acid from
correction of HIV-related facial
lipoatrophy to aging-related facial
contour deficiencies, 1001

lenalidomide in AIDS-related Kaposi sarcoma
(CR), 210

liposomal daunorubicin in HIV-related
Kaposi’s sarcoma (CTRI), 212

PTC299 in HIV-related Kaposi sarcoma (CR),
211

syrphus and lues maligna in, a
nodulocutaneous disease that still
lingers after all these centuries (RR),
1072

Hormonal therapy, advantages of oral
contraceptives and spironolactone for
women with acne (DP), 941

Hyaluronic acid (HA)
bilateral comparison study of pimecrolimus
cream 1% and ceramide-HA
emollient foam in atopic dermatitis, 666

commentary on rheological evaluation of the
physical properties of HA dermal
fillers (letter to the editor), 964

efficacy and tolerability of new monophasic
double-crosslinked HA filler for
deep lines and wrinkles, 134

efficacy of cream-based novel formulations of
HA of different molecular weights in
anti-wrinkle treatment, 990

guide to temporal fossa augmentation with
small gel particle HA dermal filler,
757

management of impending necrosis
associated with soft tissue filler
injections (CR), 1007

new face of fillers: why evidence and
experience both count (letter to the
editor), 964

open-label pilot study on effectiveness and
safety in lip augmentation, 145

Restylane for lip augmentation (PP), 684

rheological evaluation of physical properties
of HA dermal fillers, 974

safety and effectiveness of small and large
gel-particle HA in correction of
perioral wrinkles, 982

solid HA tailored to fix fine wrinkles (PP), 1341

tower technique for injection of, 1277

Hydrogels, polyacrylamide, characteristics of
different products, 1270

Hydroquinone, evaluation of prescription strength
4% hydroquinone/10% L-ascorbic acid
treatment system for photodamage in
normal to oily skin, 1455

Hyperdynamic vertical glabellar furrows,
corrugator supercilli muscle terminal
nerve ablation using novel thread
technique for treatment of, 762

Hyperhidrosis, axillary, same-patient prospective
comparison and literature review of
Botox versus Dysport for (CR), 1013

Hyperkeratosis of scalp and alopecia in children
of color, 511

Hyperpigmentation

La Roche-Posay introduces new products
(PP), 938

natural therapies for, s11 (September), s15
(September)

in nephrogenic systemic fibrosis, case report
and literature review on (RR), 622

post-inflammatory, and acne in patients with
skin of color, s13 (June)

post-inflammatory, efficacy and safety of
azelaic acid gel 15% in acne and,
586

post-inflammatory, strategies minimizing, in
treatment of acne patients with skin
of color (DP), s25 (December)

Q-switched laser treatment of amiodarone
pigmentation (CR), 1316

Hypersensitivity reactions during selective
serotonin reuptake inhibitor therapy
resulting in acquired cutis laxa (RR), 215

Hypomelanosis, progressive macular, 502
I

Ibuprofen, cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160
IDP-107, dose-ranging study on safety and efficacy in acne vulgaris (CTR), 426
Imatinib
in mucosal or acral/entiginous melanoma (CTR), 208
pigmentary changes in patient treatment with (CR), 1062
Imiquimod
in combination with cryotherapy in treatment of hypertrophic actinic keratosis (CTR), 426
compared to cryotherapy in actinic keratoses, lesion clearance, safety, and skin quality outcomes in, 1432
FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552
Graceway receives FDA approval for Zyclara Cream 2.5% for actinic keratosis (PP), 1076
long-term sustained complete clearance of actinic keratoses of face or balding scalp after treatment with, 165
with Nd:YAG laser for tattoo removal (CTR), 1342
optimal use in keloids (NVRI), 548
regression of internal melanoma metastases after topical application of (CR), 302
review of off-label clinical applications, 1300
Taro receives FDA approval for imiquimod 5% cream (PP), 683
treatment of actinic keratosis of face with imiquimod cream followed by photodynamic therapy (CTR), 426
ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
Immune function
autoimmune-mediated blisters (RR), 491
CD70 and Th17 involvement in human contact sensitivity (BC), 1192
fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient (CR), 418
inflammation in rosacea and acne, and implications for patient care, 586
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
T cell repertoire analysis of immune mediated skin diseases (CTR), 936
Immunoglobulin, intravenous, with or without cyclophosphamide in pemphigus (CTR), 1077
Immunosuppression
case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenograft matrix scaffolds (RR), 545
viral-associated trichodysplasia of, in renal transplant patient (RR), 422
Impact Factor Ranking of JDD (editorial), 1234
Impedance measurements, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using, 1116
IncobotulinumtoxinA
FDA approval for glabellar lines (PP), 1076
treatment of nostalgia paresthetica with (CTR), 91
Inflammation
efficacy and safety of azaelic acid gel
15% in post-inflammatory hyperpigmentation and acne, 586
post-inflammatory hyperpigmentation and acne in patients with skin of color, s13 (June)
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
in rosacea and acne, implications for patient care, 614
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
Infliximab, review of psoriasis treatment in 120 patients on therapy for a minimum of one year, 539
Intense pulsed light photorejuvenation, histological and immunohistochemical evaluation of, 1246
Interferon
efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403
FDA approves Sylatron to treat melanoma (PP), 684
Helix Biopharma Corp. files clinical hold for nalfurafine hydrochloride for topical treatment of psoriasis (letter to the editor), 240
International alliance of JDD (editorial), 581
Intravenous immunoglobulin with or without cyclophosphamide in pemphigus (CTR), 1077
Iododema following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
loheal, fixed drug eruption associated with intravenous contrast media (CR), 802
Iplimumab, FDA approval of (PP), 552
Irritation of skin from treatment
patient experience and management of dryness and irritation from acne treatment, 695
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
in topical rosacea therapy, vehicle formulations affecting, 627
Isotretinoin
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
Isotretinoin does not prolong QT intervals depression associated with, 409
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793}

J

Journal of Drugs in Dermatology
International alliance of (editorial), 581
receives impact factor ranking of 1.954 (editorial), 1234

K

Kaposi sarcoma, AIDS and HIV-related
lenalidomide in (CTR), 210
liposomal daunorubicin in (CTR), 212
PTC299 in (CTR), 211
Keloids
advances in treatment of, 468
new treatments in (NVR), 548
Keratoacanthoma
clinical evidence for activity of tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
treatment of vitiligo with melanoctye-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
Keratocanthoma, eruptive squamous cell carcinomas with keratocanthoma-like features in patients treated with sorafenib (CR), 308
Kidneys
alefacept therapy for nephrogenic systemic fibrosis (CR), 922
chloracne-like drug eruption associated with sorafenib in metastatic renal cell carcinoma (CR), 1331
clinical clues and patterns in biopsy diagnosis of cutaneous metastases of renal carcinoma (NVR), 678, 930
is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413
melanoma in renal transplant patient (RR), 808
nephrogenic systemic fibrosis case report and literature review (RR), 622
randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in renal disease (CTR), 91
viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422
Koebner phenomenon, tattoo sites and psoriasis (CR), 1199
Kojic acid
in natural therapies for hyperpigmentation, s17 (September)
KRT14 mutation
in epidermolysis bullosa simplex, evaluation of efficacy in, 1413
L

Lanthanum carbonate, evaluation of efficacy in calciphylaxis (CTR), 1342
Laser technology
advances in laser hair removal in skin of color, 1235
Alma Lasers introduces iPixel fractional ablative technology (PP), 805
best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20
INDEX OF ARTICLES

Lipoatrophy, facial, evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

Lipolysis, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103

Liposuction, safety of tumescent and laser-assisted liposuction, review of literature on, 1363

Liver cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930

review of chemopreventative effects of oral retinoids for, 1292

sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308

Lues maligna, erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335

a nodulocutaneous disease that still lingers after all these centuries (RR), 1072

Lung cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930

Lupus erythematosus, FDA approves Benlysta for (PP), 806

is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413

manifestations and treatment of (NVR), 1212, 1474

LY2439821 in moderate-to-severe psoriasis (CTR), 94

Lymph nodes, comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207

Lymphadenoma, cutaneous, Mohs micrographic surgery for (CR), 1324

Lymphoma, clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930

diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213

review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292

study evaluating two dose levels of Tar guterin capsules in refractory cutaneous T-cell lymphoma (CTR), 209

INDEX OF ARTICLES

M

Mallow, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

Marsh horsetail, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

Matrix scaffolds, xenogenic, case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and (RR), 545

burn scar appearance after fractional carbon dioxide laser treatment (CTR), 96

in combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125

comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62

comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1295

cconfocal scanning laser microscopy, 21 diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
effects of pulsed-dyed laser on scar formation (CTR), 96
evaluation of clinical improvement in acne scars and active acne in 1540 nm non-ablative fractional laser treatment, 907

FDA clearance of PinPointe FootLaser for nail fungus (PP), 104

FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341

fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)

multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352

multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266

nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103
	novel 0.65 millisecond pulsed 1064 nm laser nonablative 1927 nm fractional resurfacing for multiplexed 1,440 and 1,320 nm fractionated laser hair removal in ethnic skin, 1266

promising future of laser and light therapy, 32 prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179

Q-switched laser treatment of amiodarone pigmentation (CR), 1316

role in onchocerciasis (NVR), 1074

safety and efficacy of cosmetic laser treatments for skin of color, 35 safety of tumescent and laser-assisted liposuction, review of literature on, 1363
topical imiquimod with Nd:YAG laser for tattoo removal (CTR), 1342

treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
treatment of dyschromia with novel 607 nm pulsed-dye laser, 388
treatment of surgical scars using pulsed dye laser (CTR), 96, 1216

XTRAC laser for psoriasis (PP), 938

Latin Americans, melanoma in, 517

Lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210

in relapsed mycosis fungoides/Sézary syndrome (CTR), 209

Lentigines, treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)

Letters to the editor

commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers, 964

doxycycline versus minocycline for management of acne, 965, 966

new face of fillers: why evidence and experience both count, 964

short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360

ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240

Leukemia clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
dasatinib in unrespectable or metastatic squamous cell skin cancer by RAI stage 0–1 chronic lymphocytic leukemia (CTR), 207

Levamisole levamisole induced necrosis of skin and neutropenia following intraoral cocaine use: a newly recognized syndrome (CR), 1204

retiform purpura from (RR), 217

Levocetirizine, and rupatadine in chronic idiopathic urticaria, comparative study of efficacy and safety, 1444

Levofloxacin, FDA approves first generic versions of (PP), 1076

Lice, FDA approves Natroba for head lice (PP), 434

Lichen planus following Tdap vaccination (CR), 1067

Licorice aesthetic benefits of natural ingredients in skin care, s12 (September)
in atopic dermatitis and other inflammatory skin diseases, s6 (September)
evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

in natural therapies for hyperpigmentation, s17 (September)

Light emitting diode (LED) systems FDA approval of Syneron LED-based skin rejuvenation system (PP), 435

self-treatment of mild-to-moderate facial acne with blue light treatment system, 596

Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215

Light therapy. See Phototherapy

Lip open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 146

randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis (CTR), 1343

Restyline for lip augmentation (PP), 684
treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240

Copyright © 2011

JOURNAL OF DRUGS IN DERMATOLOGY

SUBJECT INDEX
clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
FDA clearance of PinPointe FootLaser for onychomycosis (PP), 104
role of lasers in onychomycosis (NVR), 1074
Nalfurafine HCl (AC-820), randomized-withdrawal phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91
Nalmefene, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
Nanotechnology, and dermatology education in United States, data from pilot survey, 1037
Nasal basal cell carcinoma, ulcerated nodular, successfully treated with imiquimod 5% cream (letter to the editor), 240
Nasolabial folds and wrinkles, azficel-T in (PP), 325
Natural ingredients
aesthetic benefits of, s10 (September) in atopic dermatitis and other inflammatory skin diseases, s6 (September)
CME: identifying natural ingredients and their use in skin care, s4 (September), s21 (September), s22 (September)
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
cosmeceutical and nutraceutical horizons, 24 defining terms in, s10 (September) evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensimetry methods, 1116
in hyperpigmentation, s11 (September), s15 (September)
randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
Stiefel/GSK introduces Illuminesse Brightening Complex (PP), 938
Nd:YAG laser and topical imiquimod for tattoo removal (CTR), 1342
Necrosis
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
levamisole induced necrosis of skin and neutrophilia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
management of impending necrosis associated with soft tissue filler injections (CR), 1007
Neodymium:YAG laser and topical imiquimod for tattoo removal (CTR), 1342
Neonates, phototherapy-induced purpura in transient porphyrinemia of (RR), 306
Neoplasia
biopsy diagnosis: clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930
levamisole induced necrosis of skin and neutrophilia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
management of impending necrosis associated with soft tissue filler injections (CR), 1007
Neotrogen: YAG laser and topical imiquimod for tattoo removal (CTR), 1342
Nitric oxide, taurine chloramine inhibits NO and taurine chloramine inhibits NO and TNF-α production in zymosan plus activated RAW 264.7 cells, 427
Nitrogen, liquid, compared to dimethyl ether and propane in cryosurgical treatment of warts, case report and review of literature on, 1174
Nitroglycerin, FDA approval for Rectiv (PP), 939
Non-steroidal anti-inflammatory agents, cutaneous reactions to, 1160
Notalgia paraesthesica treatment with Xeomim (CTR), 91
Nova Southeastern University College of...
promising future of laser and light therapy, 32 randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
severe cutaneous reaction to photodynamic therapy with blue light (CR), 1057
Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215
treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
XTRAC laser for psoriasis (PP), 938

Pigmentation
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as a topical treatment for melasma, 1025
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
effectiveness of topical tacrolimus for vitiligo in skin of color patients, 507
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
melasma in Latin Americans, 517
natural therapies for hyperpigmentation, s11 (September), s15 (September)
novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926
pigmentary changes in patient treatment with imatinib (CR), 1062
pilot study using reflectance confocal microscopy in assessment of novel formulation for melasma, 1260
progressive macular hypopigmentation, 502
Q-switched laser treatment of amiodarone pigmentation (CR), 1316
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
topical retinoids for pigmented skin, 483
treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
treatment of vitiligo with melanoocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Pimecrolimus
bilateral comparative study of pimecrolimus cream 1% and medical device cream in atopic dermatitis, 735
bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in atopic dermatitis, 666
Pipeline Previews (PP)
Abbott files for 510(k) clearance for vitamin D assay, 684
Abbott withdraws briakinumab from FDA review (PP), 435
Acanya gel acne therapy available in pump, 1479
Allergan cell-based assay for BOTOX, 938
Alma Lasers introduces Pjavel fractional ablative therapy, 805
anakina effective for severe Muckle-Wells syndrome, 214
Cardium Therapeutics announces FDA 510(k) clearance for Exellagel, 1478
Cleure launches FDA-approved broad-spectrum sunscreen, 1076
CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system, 1478
Crutchedfield Dermatology now offers Selphyl wrinkle treatment, 213
Ellman International introduces Pelleved to European market, 938
EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator, 435
Eucerin launches campaign in Europe and Asia, 1076
FDA approves Benlysta for lupus erythematosus, 806
FDA approves Botox for chronic migraines, 104
FDA approves Ceftriafor for MRSA, 104
FDA approves Fibrocell Science LAVIV, 939
FDA approves first generic versions of levofloxacin, 1076
FDA approves Gardasil to prevent anal cancer, 103
FDA approves Glenmark Generics muiprocin 2% ointment, 939
FDA approves iplilumab, 552
FDA approves Natroba for head lice, 434
FDA approves Rectiv (nitrergolycin) ointment, 939
FDA approves Rituxan with corticosteroids for severe vasculitis, 683
FDA approves Sorilux (calcipotriene) foam, 103
FDA approves Sylatro to treat melanoma, 684
FDA approves Syneron LED-based skin rejuvenation system, 435
FDA approves Xemoin (ibocoulotumitoxinA), 1076
FDA approves Zyclara Cream 3.75% for external genital warts, 552
FDA bans skin whitening products containing mercury, 1215
FDA clearance of PinPointe FootLaser for nail fungus, 104
FDA gives provisional approval to MelaFind device, 1340
FDA grants clearance for HairMax Dual 12 home-use laser phototherapy device, 1341
FDA panel votes in favor of MelaFind skin cancer detection device, 213
FDA warming letter to Jaba Labs, 552
Fibrocell Science, Inc. and aacif-1T, 325, 939
Genentech submits New Drug Application to FDA, 1340
Gly-Sal Acne Body Spray, 434
Graceyce receives FDA approval for Zyclara Cream 2.5% for actinic keratitis, 1076
Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b, 1478
herpes zoster vaccine reduces zoster risk, 324
injection lipolysis of abdominal subcutaneous fat yields results, 103
La Roche-Posay introduces new products, 938
LEO Pharma launches $0 copay program for Taclonex plaque psoriasis treatments, 683
long-term efficacy and potencies of botulinum toxin A and B, 324
management of pain associated with debridement of leg ulcers, 324
methemoglobinemia risk from benzocaine topical products, 684
new analysis demonstrates activity in relapsed or refractory transformed mycosis fungoides, 213
New Drug Application for vemurafenib in advanced skin cancer, 805
New Drug Application for Yaupon's mechlorethamine hydrochloride, 1478
nonablative 1927 nm fractional resurfacing for actinic keratoses, 103
positive results in advanced melanoma drug study, 103
Proventus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis, 806
psoriasis drugs not linked to increased heart risks, 1215
Restylane for lip augmentation, 684
resveratrol-containing gel for acne, 434
ROGAINE introduces UnscentedTopical Foam, 1076
Safe Cosmetics Act of 2011, 1215
Sagent Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection, 1478
Sauwove Health, Inc. dermaPACE device for diabetic foot ulcers, 326
solid hyaluronic acid tailored to fine wrinkles, 1341
Stiefel/GSK introduces Illuminumese Brightening Complex, 938
study confirms sunscreen prevents melanoma, 1062
Syneron devices at 22nd World Congress of Dermatology, 805
Taenda Luxe Device for home treatment of periorbital wrinkles, 1215
Taro receives FDA approval for imiquimod 5% cream, 683
topical neurotoxin erases crow's feet, 1341
Topix Pharmaceuticals, Inc. releases Repifenix Resurfrix Skin Barrier Healing Ointment, 805
XTRAC laser for psoriasis, 938
Zelboraf (vemurafenib) receives FDA approval, 1215

PLX4032, positive results in melanoma study (PP), 103
Poly-L-lactic acid (PLLA), evolution of injectable PLLA from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
Polyacrylamide hydrogels, characteristics of different products, 1370
Polyangiitis, microscopic, FDA approval of Rituxan with corticosteroids for (PP), 683
Polyphenols, green tea
aesthetic benefits of natural ingredients in skin care, s12 (September)
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts,
INDEX OF ARTICLES

Pomegranate, aesthetic benefits of natural ingredients in skin care, s12 (September)

Porphyriaemia of neonate, transient, phototherapy-induced purpura in (RR), 306

Post-herpetic itch resolved with gabapentin (CR), 85

Post-inflammatory hyperpigmentation and acne in patients with skin of color, s13 (June)

efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586

strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)

Povidone-iodine, chemical burn from (CR), 414

Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213

Prevention
FDA approves Gardasil to prevent anal cancer (PP), 325

review of chemopreventative effects of oral retinoids for internal neoplasms, 1292

study confirms sunscreen prevents melanoma (PP), 213

PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) (PP), 213

Prurigo nodularis, CC-10004 for (CTR), 91

Pruritus
acupressure for pruritus in atopic dermatitis (CTR), 90

CC-10004 for prurigo nodularis (CTR), 91

efficacy, safety, and tolerability of topical nalmefen for pruritus in atopic dermatitis, 853

efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis (CTR), 1486

post-herpetic itch resolved with gabapentin (CR), 85

randomized withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus (CTR), 91

treatment of notalgia paresthetica with acitretin, 409

treatment of psoriasis with tolcapone (TRIN遏), 370

treatment of psoriasis with tolcapone (TRIN遏), 370

Psoriasis
Abbott withdraws briakinumab from FDA review (PP), 435

adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 386

assessment of national trends in acitretin treatment of, 873

association of depression with acitretin in, 409

Bicillin-LA versus placebo for chronic plaque-type psoriasis unresponsive to topical medications (CTR), 317

central serous chorioretinopathy associated with topical corticosteroids in (CR), 918

CP-690-550 ointment for chronic plaque psoriasis (CTR), 316

diffuse large B-cell lymphoma associated with biologic and other investigational agents in (CR), 80

dose finding study of AEBO71 assessing psoriasis area and severity index in plaque psoriasis (CTR), 92

dose-ranging study of AlN457 in moderate-to-severe chronic plaque-type psoriasis (CTR), 93

efficacy and side effects of low-dose acitretin in (CTR), 95

FDA approval of Sorilux (calcipotriene) foam in (PP), 103

frequency of thrombocytopenia in tumor necrosis factor- alpha inhibitor treatment, 280

genes in (NVR), 1337

impact of biologics on disease and treatment burden of, 189

increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843

LEO Pharma launches $20 copay program for Taclonex plaque psoriasis treatments (PP), 683

literature review on acitretin in, 772

long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis, 851

metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900

multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158

Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-alpha blockers (CR), 914

one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688

open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396

Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806

psoriasis drugs not linked to increased heart risks (PP), 1219

randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 865

randomized study of PH-10 for psoriasis (PP), 806

treatment of severe chronic plaque-type psoriasis with etanercept, 866

review of chemopreventative effects of oral retinoids for internal neoplasms in, 1292

review of infliximab treatment in 120 patients on therapy for a minimum of one year, 539

Psoriasis drugs not linked to increased heart risks (PP), 1219

randomized placebo-controlled double-blind study on efficacy of citrus bioflavonoid blend in senile purpura, 719

retiform, levamisole-induced (RR), 217

PsORS genes in psoriasis (NVR), 1337

Psychiatric disorders, increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843

PTC299 in HIV-related Kaposi sarcoma (CTR), 211

Pulsed dye laser
effects on scar formation (CTR), 96

treatment of dyschromia with novel 607 nm pulsed-dye laser, 388

treatment of surgical scars using (CTR), 96, 1216

Purpura
phototherapy-induced, in transient porphyriaemia of neonate (RR), 306

randomized placebo-controlled double-blind study on efficacy of citrus bioflavonoid blend in senile purpura, 719

retiform, levamisole-induced (RR), 217

Pyoderma gangrenosum
following breast reconstructive surgery, case report on treatment with immunosuppression and adjunctive xenogenic matrix scaffolds (RR), 545

treatment with topical crushed dapsone (CR), 1059

Q

Q-switched laser treatment of amiodarone pigmentation (CR), 1316

treating lentigines in Asian patients with Q-switched ruby and krypton laser (DP), s14 (December)

QT intervals and QT dispersion, isotretinoin does not prolong QT intervals and QT
INDEX OF ARTICLES

R

Race/ethnicity
acne in patients with skin of color, s13 (June)
advances in laser hair removal in skin of color, 1235
advances in treatment of keloids, 468
best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
community-based study of skin conditions and concerns in South Asian Americans (BC), s24
cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)
dermal fillers in skin of color, 494
diole 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
effectiveness of topical tacrolimus for vitiligo in skin of color, 507
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)
melanoma in Latin Americans, s17
novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or aesthesia (DP), s10 (December)
progressive macular hypomelanosis, 502
retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866
safety and efficacy of cosmetic laser treatments for skin of color, 35
scalp hyperkeratosis and alopecia in children of color, 511
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654
topical retinoids for pigmented skin, 483
treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)

Radiation therapy
electronic brachytherapy for non-melanoma skin cancer treatment (CTR), 206
phase 2 trial of erlotinib prior to surgery or radiation in squamous cell cancer (CTR), 207
study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides (CTR), 209

Radiofrequency device, multiple facial burns with newThermage CPT system (CR), 1320

Radiodine ablation of thyroid
following (RR), 1070
Rapamycin, recent advances and future directions in medical management of skin disease, 28
RAW 264.7 cells, taurine chloramine inhibits NO and TNF-α production in zymosan plus interferon-γ activated RAW 264.7 cells, 659
Reactive oxygen species
assessment of kinetics of antioxidative capacity of topical antioxidants, 262
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 755
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
Reconstructive surgery
case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogenic matrix scaffolds (RR), 545
modified Tripier flap for lateral eyelid reconstruction (CR), 199
Red light source, safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
Reflectance confocal microscopy (RCM), pilot study using RCM in assessment of novel formulation for melasma, 1260
REGN668, sequential ascending dose study on safety and tolerability in atopic dermatitis (CTR), 314
Renal conditions. See Kidneys
Resident Rounds (RR)
Albert Einstein College of Medicine Unified Division of Dermatology Residency Program program spotlight, 1122
autoimmune-mediated blisters (for the Boards), 491
case of trichomyosis axillaris and erythrasma, 1472
case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogenic matrix scaffolds, 545
cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa, 215
dermal melanoma in transplant patient, 808
Eastern Virginia Medical School Dermatology Residency Program program spotlight, 344
erosive and desquamative syphilis associated with mucositis in setting of AIDS, 1335
eruptive plexiform schwannomas in child with neurofibromatosis I, 1210
fulminant dermatomyositis with flagellate erythema, 902
hair findings board review, 1464
Harvard Combined Dermatology Residency Training Program program spotlight, 186
high-yield dermatologic signs in Harvard Combined Residency Training Program, 197
highly virulent melanoma in transplant patient, 306
inguinal lymphadenopathy in a patient with HIV infection, 849
invasive squamous cell carcinoma treated with aggressive whole body phototherapy, 1310
iododerma following radioiodine ablation of thyroid for Graves disease, 1070
iodocorticotropic hormone (CTH) levels for assessment of cGMP levels in cryopreserved melanoma tissue, 1294
levamisole-induced retiform purpura, 217
nephrogenic systemic fibrosis: case report and literature review, 622
noduleulcerative disease that still lingers after all these centuries, 1072
Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program program spotlight, 467
pediatric vascular anomalies, 893
photomedicine board review facts, 750
phototherapy-induced purpura in transient porphyriaemia of neonate, 306
reported adverse effects of isotretinoin and systemic corticosteroids, 287
sound-alike and look-alike terms in dermatology, 1196
study aid: diagnosis and associations, 611
ticks of dermatologic significance, 385
reconstruction (CR), 199
University of California Davis Department of Dermatology Residency Training Program program spotlight, 253
University of California Irvine Department of Dermatology Residency Training Program program spotlight, 593
University of California San Francisco Department of Dermatology Residency Training Program program spotlight, 883
University of Connecticut Dermatology Residency program spotlight, 1452
University of Louisville Dermatology Residency Training Program program spotlight, 1289
University of Massachusetts Medical School Dermatology Residency Program program spotlight, 716
University of Texas Southwestern Medical Center Dermatology Residency Program program spotlight, 1016
viral-associated trichodysplasia of immunosuppression in renal transplant patient, 422

Resident Spotlight (RS)
compariison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and Melafind, 1078
winning poster: phase 2 open-label investigator-initiated study of safety and efficacy of apraimast in recalcitrant contact or atopic dermatitis, 928
winning poster: predictive factors for severity of scar formation after skin cancer surgeries, 810

Resveratrol-containing gel for acne (PP), 434

Retinoids
adapalene gel 0.3% in atrophic acne scars (CTR), 96
assessment of national trends in acitretin treatment of psoriasis, 873
in combination treatment for moderate-to-severe acne (CTR), 90
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
comparison of retinol 1.0% and tretinoin cream 0.05% in patients with melasma, 1439
intralymphatic histiocytosis associated with orthopedic implants, 1208
iododerma following radioiodine ablation of thyroid for Graves disease, 1070
iodocorticotropic hormone (CTH) levels for assessment of cGMP levels in cryopreserved melanoma tissue, 1294
levamisole-induced retiform purpura, 217
nephrogenic systemic fibrosis: case report and literature review, 622
noduleulcerative disease that still lingers after all these centuries, 1072
Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program program spotlight, 467
pediatric vascular anomalies, 893
photomedicine board review facts, 750
phototherapy-induced purpura in transient porphyriaemia of neonate, 306
reported adverse effects of isotretinoin and systemic corticosteroids, 287
sound-alike and look-alike terms in dermatology, 1196
study aid: diagnosis and associations, 611
ticks of dermatologic significance, 385
reconstruction (CR), 199
University of California Davis Department of Dermatology Residency Training Program program spotlight, 253
University of California Irvine Department of Dermatology Residency Training Program program spotlight, 593
University of California San Francisco Department of Dermatology Residency Training Program program spotlight, 883
University of Connecticut Dermatology Residency program spotlight, 1452
University of Louisville Dermatology Residency Training Program program spotlight, 1289
University of Massachusetts Medical School Dermatology Residency Program program spotlight, 716
University of Texas Southwestern Medical Center Dermatology Residency Program program spotlight, 1016
viral-associated trichodysplasia of immunosuppression in renal transplant patient, 422

Resident Spotlight (RS)
compariison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and Melafind, 1078
winning poster: phase 2 open-label investigator-initiated study of safety and efficacy of apraimast in recalcitrant contact or atopic dermatitis, 928
winning poster: predictive factors for severity of scar formation after skin cancer surgeries, 810

Resveratrol-containing gel for acne (PP), 434

Retinoids
adapalene gel 0.3% in atrophic acne scars (CTR), 96
0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
effect of retinoid pretreatment on outcomes of photodynamic therapy for actinic keratosis of hand and forearm, 1124
Epideluo pediatric acne study (CTR), 90, 312
isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
literature review on acitretin in dermatology, 772
randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
reported adverse effects of systemic corticosteroids and isotretinoin (RR), 287
rethinking treatment of acne in severe patient, s8 (June)
review of chemopreventative effects for internal neoplasms, 1292
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
topical, for pigmented skin, 483
in topical fixed-combination therapy and topical monotherapy in acne, evidence-based review on, 636
Retinol, comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
Retinopathy, central serous choroideratopathy associated with topical corticosteroids in psoriasis (CR), 918
Rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974
commentary on (letter to the editor), 964
Rhytids (rhytides). See Wrinkles
Rituximab
dosing in refractory pemphigus vulgaris in adolescent male (CR), 202
FDA approval of Rituxan with corticosteroids in refractory pemphigus vulgaris in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
open-label study of safety and efficacy of sertaconazole nitrate in seborrhoeic dermatitis, 895
phase 3 efficacy and study of ASP015K in moderate-to-severe plaque psoriasis (CTR), 1216
phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
safety and efficacy of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982
safety and efficacy of clindamycin phosphate 1.25%-benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
safety and efficacy of clobetasol propionate 0.05% ointment in plaque psoriasis, 158
safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
safety of tumescent and laser-assisted liposuction, review of literature on, 1363
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis (CTR), 314
study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315
Salicylic acid in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
in Gly-Sal Acne Body Spray (PP), 434
Salmeterol xinafoate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
Sarcoma, AIDS and HIV-related sarcoma,
Salen[32] complex in (CTR), 220
liposomal daunorubicin in (CTR), 212
PTC299 in (CTR), 211

RT001, topical neurotoxin erases crow’s feet (PP), 1341
Rupatadine and levocetirizine in chronic idiopathic urticaria, comparative study of efficacy and safety, 1444

Safe Cosmetics Act of 2011 (PP), 1215
Safety issues
in blue versus red light sources for MAL-PDT in photodamaged skin, 53
in calcium hydroxyapatite rejuvenation of aging hand, 52-week study of, 47
clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
clinical trial safety and mortality analysis of etanercept across approved indications, 289
comparative study of efficacy and safety of rupatadine and levocetirizine in chronic idiopathic urticaria, 1444
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
in comparison of cryotherapy and imiquimod for actinic keratoses, 1432
in cosmetic laser treatments for skin of color, 39
in dermal fillers in skin of color population, 494
diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris (CTR), 426
double-blind randomized vehicle-controlled study on efficacy and safety of nafenfl 2% cream in tinea cruris, 1142
double-blind randomized vehicle-controlled study on efficacy and safety of nafenfl 2% cream in tinea pedis, 1282
efficacy, safety, and tolerability of SRT0174 cream for pruritus in atopic dermatitis, 853
efficacy and safety of different concentrations of ZK245186 in atopic dermatitis (CTR), 313
efficacy and safety of sequential treatment to etanercept in moderate-to-severe chronic plaque psoriasis (CTR), 1216
efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
safety of tumescent and laser-assisted liposuction, review of literature on, 1363
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis (CTR), 314
study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315
Salicylic acid in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
in Gly-Sal Acne Body Spray (PP), 434
Salmeterol xinafoate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
Sarcoma, AIDS and HIV-related sarcoma,
Salen[32] complex in (CTR), 220
liposomal daunorubicin in (CTR), 212
PTC299 in (CTR), 211
Scalp cooling in prevention of chemotherapy-induced alopecia (CTR), 936

Scalp lesions
long-term complete sustained control of actinic keratoses of face or balding scalp after imiquimod treatment, 95
randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
scalp hyperkeratosis and alopecia in children of color, 511

Scars/scarring
adapalene gel in treatment of atrophic acne scars (CTR), 96
burn scar appearance after fractional carbon dioxide laser treatment (CTR), 96
effects of pulsed-dyed laser on scar formation (CTR), 96
evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), 1216
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
treatment of surgical scars using pulsed dye laser (CTR), 96, 1216
winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810

Schwannoma, eruptive plexiform, in child with neurofibromatosis I (RR), 1210

Screening, scars (October)
early detection and cure of melanoma in serial screening, 244

Seborrheic dermatitis, open-label study of safety and efficacy of sertaconazole nitrate in, 895

Secukinumab, safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216

Serotonin reuptake inhibitor therapy, selective, cutaneous hypersensitivity to resulting in acrodermatitis continua lupoides (October)
Sertaconazole nitrate
open-label study of safety and efficacy in seborrheic dermatitis, 895
treatment of interdigital tinea pedis with once-daily therapy with, 1135

Sézary syndrome. See Mycosis fungoides/Sézary syndrome

Skin barrier function
clinical relevance of maintaining structural and functional integrity of stratum corneum (October)
comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
effects of novel fluocinonide cream formulation on, in atopic dermatitis, 171
managing epidermal barrier function in treatment of dermatoses, s13

new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 744
role of stratum corneum in healthy and diseased skin (editorial), s4

Topix Pharmaceuticals, Inc. releases Replichen ResurFix Skin Barrier Healing Ointment (PP), 806

Skin cancer
cancer: this war is personal (editorial), 237
clinical trial of Dermacorder for detecting malignant skin lesions (CTR), 317
comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
cardiovascular lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318
dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0 chronic lymphocytic leukemia (CTR), 207
dermal melanoma in renal transplant patient (RR), 803
early detection and cure in serial screening for melanoma, 244
electronic brachytherapy for non-melanoma skin cancer treatment (CTR), 206
eruptive squamous cell carcinoma with keratoacanthoma-like features in Fitzpatrick skin type III (tractability), 308
FDA gives provisional approval to MelaFind device (PP), 1340
FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
imatinib in mucosal and cutaneous squamous cell melanoma (CTR), 208
lessons from an exemplary physician in private setting (editorial), 238
Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811
Mohs micrographic surgery for cutaneous lymphangioendothelioma (CR), 1324
new drug applications for vemurafenib in advanced skin cancer (PP), 805
novel devices for diagnosis and treatment, 21 phase 2 trial of erlotinib prior to surgery or radiation in (CTR), 207
sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207
spectral diagnosis of cutaneous malignancies (October)
study confirms sunscreen prevents melanoma (PP), 213
study of ultrasonography with elastography in skin neoplasms (CTR), 319
study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206
three-dimensional Mohs surgery, a new concept, 1273
trends in treatment and detection of, 16 three-stage surgical treatment of, 257 ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
unresectable or metastatic, dasatinib in (CTR), 207
use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision (December)
winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810

Skin Health Experimental Product (SHEP), phase 2 double-blind randomized placebo-controlled trial of novel nutritional supplement product to promote healthy skin, 1106

Skin lightening products
FDA ban on skin whitening products containing mercury (PP), 1215
natural therapies for hyperpigmentation, s11 (September), s15 (September)

Skin of color
acne in patients with, s13 (June) advances in laser hair removal in, 1235
advances in treatment of keloids, 468
best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
cosmetic pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
clinical pearls for dermal filler enhancement in skin of color, a unique challenge (editorial), s4 (December)
dermal fillers in, 494
diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
effectiveness of topical tetracycline for vitiligo in, 507
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)
melasma in Latin Americans, 517
novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
progress made, challenges remain (editorial), 459
progressive macular hypopigmentation, 502
retrospective study of racial and ethnic variations in primary treatment with etanercept, 866
safety and efficacy of cosmetic laser treatments for, 35
scrap hyperkeratosis and alopecia in children of color, 511
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with (DP), s25 (December)
connective tissue diseases (RR), 1314
integrated basic and clinical sciences conference (RR), 1045
nanotechnology and dermatology education in United States, data from pilot survey, 1037
Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program (RR), 467, 491, 545
pediatric vascular anomalies (RR), 893
photomedicine board review facts (RR), 750
sound-alike and look-alike terms in dermatology (RR), 1196
study aid: diagnosis and associations (RR), 611
University of California Davis Department of Dermatology Residency Training Program (RR), 253, 287, 306
University of California Irvine Department of Dermatology Residency Training Program (RR), 593, 611, 622
University of California San Francisco Department of Dermatology Residency Training Program (RR), 883, 933, 902
University of Connecticut School of Medicine Dermatology Residency (RR), 1452, 1464, 1472
University of Louisville School of Medicine Dermatology Residency Training Program (RR), 1289, 1314, 1335
University of Massachusetts Medical School Dermatology Residency Program (RR), 716, 750, 808
University of Texas Southwestern Medical Center Dermatology Residency Program (RR), 1016, 1045, 1070, 1072
Transsepidermal water loss
effects of novel fluocinonide cream formulation on skin barrier function in atopnic dermatitis, 171
new body moisturizer increases skin hydration and improves atopnic dermatitis symptoms in children and adults, 744
Transplant recipients
melanoma in renal transplant patient (RR), 808
viral-associated trichodyplasia of immunosuppression in renal transplant patient (RR), 422
Tretinoin
in combination treatment for moderate-to-severe acne (CTR), 90
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melanoma, 1439
comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
in topical monotherapy for acne, compared to fixed-combination therapy, 636
Triage in Mohs micrographic surgery, 257
Trichodyplasia of immunosuppression, viral-associated, in renal transplant patient (RR), 422
Trichomycosis axillaris, and erythrasma, case of (RR), 1472
Triplet flap, modified, for lateral eyelid reconstruction (CR), 199
Triple compression bandage and chitosan gel in treatment of venous leg ulcers, 75
Tumec, aesthetic benefits of natural ingredients in skin care, s12 (September)
Tumescent liposuction, safety of tumescent and laser-assisted liposuction, review of literature on, 1363
Tumor necrosis factor-α
adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
clinical trial safety and mortality analysis in patients receiving etanercept across approved indications, 289
etanercept as sole treatment for grade I acute graft versus host disease (CTR), 1487
frequency of thrombocytopenia in psoriasis treated with tumor necrosis factor-α inhibitors, 290
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-α blockers (CR), 914
open-label prospective cohort study on efficacy and safety of secukinumab treatment in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
retrospective study of social and ethnic variations in psoriasis treatment with etanercept, 866
review of infiximab treatment for psoriasis in 120 patients on therapy for a minimum of one year, 539
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
taurine chloramine inhibits NO and TNF-α production in zymosan plus interferon-γ activated RAW 264.7 cells, 659
topical calciptriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
treatment of recalcitrant generalized granuloma annulare with adalimumab (CR), 1466
Tyrosinase, aesthetic benefits of natural ingredients in skin care, s11 (September)
Tyrosinase inhibitors, aesthetic benefits of natural ingredients in skin care, s11 (September)
U
Ulcers
deramax device for diabetic foot ulcers (RR), 325
novel treatment for ulcerative calcinosis cutis, 1042
pain management in debridement of leg ulcers (PP), 324
Topix Pharmaceuticals releases Repenlix ResuFix Skin Barrier Healing Ointment (PP), 805
treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
ulcerated nodular basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
Ultrasonography with elastography in skin neoplasms (CTR), 319
Ultraviolet (UV) radiation exposure
adalimumab plus narrowband UV B light phototherapy for moderate to severe psoriasis, 366
assessment of antioxidative capacity kinetics of topical antioxidants in, 262
Cleure launches FDA-approved broad-spectrum sunscreen (PP), 1076
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
impact on UVB-SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150
in keloids (NVI), 550
multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
Unified Division of Dermatology of Albert Einstein College of Medicine
eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
intralymphatic histiocytosis associated with orthopedic implants (RR), 1208
program spotlight on Residency Program (RR), 1122
sound-alike and look-alike terms in dermatology (RR), 1196
University of California–Davis
phototherapy-induced purpura in transient porphyrimenia of neonate (RR), 306
program spotlight on Department of Dermatology Residency Training Program (RR), 253
reported adverse effects of isotretinoin and systemic corticosteroids (RR), 287
University of California–Irvine
nephrogenic systemic fibrosis: case report and literature review (RR), 622
program spotlight on Dermatology Residency Training Program (RR), 593
study aid: diagnosis and associations (RR), 611
University of California–San Francisco
fulminant dermatomyositis with flagellate erythema (RR), 902
pediatric vascular anomalies (RR), 893
program spotlight on Department of Dermatology Residency Training Program (RR), 883
University of Connecticut School of Medicine
case of trichomycosis axillaris and erythrasma (RR), 1472
hair findings board review (RR), 1464
program spotlight on Dermatology Residency (RR), 1455
University of Louisville School of Medicine
erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335
highlights of common autoimmune connective tissue diseases (RR), 1314
program spotlight on Dermatology Residency Training Program (RR), 593
study aid: diagnosis and associations (RR), 611
University of California San Francisco
program spotlight on Dermatology Residency Training Program (RR), 324
INDEX OF ARTICLES

W

Warts
comparison of dimethyl ether and propane
to liquid nitrogen in cryosurgical
treatment of, case report and review of
literature on, 1174
FDA approves Zyclara Cream 3.75% for
external genital warts (PP), 552
metabolic syndrome and surrogate markers
of increased cardiovascular risk in
children with moderate-to-severe
psoriasis compared to age-matched
population with warts (BC), 360
Wegener’s granulomatosis, FDA approval of
Rituxan with corticosteroids for (PP),
683
Wnt, hair regrowth following a Wnt- and
follicin-containing treatment, safety and
efficacy in first-in-man phase 1
clinical trials, 1308
World Congress of Dermatology, Syneron devices
introduced at (PP), 805

Wound healing
from basic science to clinical practice and
beyond (NVR), 427
Cardium Therapeutics announces FDA 510(k)
clearance for Excellagen (PP), 1478
case report of pyoderma gangrenosum
following breast reconstructive
surgery treated with immunosuppression and
adjunctive xenogeneic matrix scaffolds (RR),
545
randomized double-blind petrolatum-
controlled study on efficacy of
oregano extract ointment in, 1168
secondary, in use of gelatin sponges in Mohs
micrographic surgery defects and
staged melanoma excisions, 68
Topix Pharmaceuticals releases RepleniX
ResurFIX Skin Barrier Healing
Ointment (PP), 805
treatment efficacy of triple bandage
compression and chitosan gel in
venous leg ulcers, 75
winning poster: predictive factors for severity of
scar formation after skin cancer
surgeries (RS), 810

Wrinkles
azeficel-T in nasolabial folds and wrinkles (PP),
325, 939
comparing clinical attributes of
abobotulinumtoxinA and
onabotulinumtoxinA using Frontalis
Rating Scale and Frontalis Activity
Measurement Standard, 1148
comparison of retinol 1.0% and tretinoin
0.02% in moderate-to-severe
photodamage and wrinkles (CTR),
1217
corrugator supercili muscle terminal
erve ablation using novel
thread technique for treatment of
hyperdynamic vertical glabellar
furrows, 762
Crutchfield Dermatology now offers Selphyl
wrinkle treatment (PP), 213
efficacy and tolerability of new monophasic
double-crosslinked hyaluronic acid
filler for deep lines and, 134
efficacy of cream-based novel formulations of
hyaluronic acid of different
molecular weights in anti-wrinkle

treatment, 990

Ellman International introduces Pellevé
Wrinkle Reduction System to
European market (PP), 938
FDA approval for Syneron LED-based skin
rejuvenation system (PP), 435
FDA approval of Xeomin
(incobotulinumtoxinA) for glabellar
lines (PP), 1076
histological and immunohistochemical
evaluation of intense pulsed light
photorejuvenation for, 1246
La Roche-Posay introduces new products
(PP), 938
multi-center clinical study and review of
fractional ablative carbon dioxide
laser resurfacing for rhytides,
photoaging, scars, and striae, 352
rapid onset of response and patient-reported
outcomes after onabotulinumtoxinA
treatment of moderate-to-severe
glabellar lines, 39
safety and effectiveness of small and large
gel-particle hyaluronic acid
in correction of perioral wrinkles, 982
safety and efficacy of calcium hydroxyapatite
for rejuvenation of aging hand, 47
solid hyaluronic acid tailored to fix fine
winkles (PP), 1341
Taenda Luxe Device for home treatment of
periobrital wrinkles (PP), 1215
topical neurotoxin eradces crow’s feet (PP),
1341
tower technique for injection of hyaluronic acid
fillers in, 1277

WS-1 fibroblast cells, complementary antioxidant
function of caffeine and green tea
polyphenols in normal human skin
fibroblasts, 753

Z

Zanolimumab, study of human monoclonal
antibody to treat mycosis fungoides and
Sézary syndrome (CTR), 1077
Zinc
and copper in natural therapies for
hyperpigmentation, s18
(Zeferon) randomized double-blind placebo-controlled
multi-center trial of zinc for herpes
simplex labialis, 1343
ZK245186 in atopic dermatitis, efficacy and safety of
different concentrations (CTR), 313
Zoster, herpes zoster vaccine reduces zoster risk
(PP), 324
Zymosan, taurine chloramine inhibits NO and
TNF-α production in zymosan plus
interferon-γ activated RAW 264.7 cells,
659